Article Information
History
- May 6, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Rajith KR Rajoli1,
- Henry Pertinez1,
- Usman Arshad1,
- Helen Box1,
- Lee Tatham1,
- Paul Curley1,
- Megan Neary1,
- Joanne Sharp1,
- Neill J Liptrott1,
- Anthony Valentijn1,
- Christopher David1,
- Steve P Rannard2,
- Ghaith Aljayyoussi3,
- Shaun H Pennington3,
- Andrew Hill1,
- Marta Boffito4,5,
- Stephen A Ward3,
- Saye H Khoo1,
- Patrick G Bray6,
- Paul M. O’Neill2,
- W. Dave Hong2,
- Giancarlo Biagini3 and
- Andrew Owen1,*
- 1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
- 2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
- 3Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
- 4Chelsea and Westminster NHS Foundation Trust and St Stephen’s AIDS Trust 4th Floor, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
- 5Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College, London, W2 1PG, UK
- 6Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK
- ↵*Author for correspondence: Professor Andrew Owen, Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, 51 Oxford Street, Liverpool L7 3NY, United Kingdom, Email - aowen{at}liverpool.ac.uk, Phone - +44 (0)151 795 7129
Posted May 06, 2020.
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
